Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Remimazolam Besylate

FDA-approved product (powder, intravenous), marketed as Byfavo.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
3 of 4

Chemical structure

Chemical structure of Remimazolam Besylate
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Sedation

Indications ChEMBL records as approved, from FDA and DailyMed labels.

WHO therapeutic group
Benzodiazepine derivatives
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against E. coli, MRSA and M. tuberculosis. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA47.5% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli42.3% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae25.2% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis51.9% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Remimazolam Besylate in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-6.5 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-7.8 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

Not yet docked: queued in the docking rundetails

Dihydrofolate reductase ↗ (MRSA)

-7.4 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Remimazolam Besylate with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Comparison of Remimazolam and Propofol Effect on Oxygenation Reservoir During Diagnostic Gastric Endoscopy

    NCT05723627 · start 2023-04-06

    Registered record
    Registry ID
    NCT05723627
    Conditions
    Diagnostic Gastric Endoscopy
    Interventions
    Remimazolam besylate; Propofol
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2023-04-06
    Completion
    2023-09-21
    Enrolment
    70

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionDiagnostic Gastric Endoscopy
    InterventionRemimazolam besylate; Propofol
    PhaseNot applicable
    Registry statusCompleted

  • Compatible Effect of Remimazolam Besylate Combined With Afentanil for ATI

    NCT06026566 · start 2023-04-01

    Registered record
    Registry ID
    NCT06026566
    Conditions
    Remimazolam; Awake Endotracheal Intubation
    Interventions
    Dos of Afentanil 20; Dos of Afentanil 30; Dos of Afentanil 40; Dos of Afentanil 50; Dos of Afentanil 60; Dos of Afentanil 70; Dos of Afentanil 80; Dos of Afentanil 90; Dos of Afentanil 100
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Unknown
    Start
    2023-04-01
    Completion
    2025-12-31
    Enrolment
    180

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionRemimazolam; Awake Endotracheal Intubation
    InterventionDos of Afentanil 20; Dos of Afentanil 30; Dos of Afentanil 40; Dos of Afentanil 50 +5 more
    PhaseNot applicable
    Registry statusUnknown

  • Total Intravenous Anesthesia for Rigid Bronchoscopy Using Remimazolam

    NCT05835713 · start 2023-04

    Registered record
    Registry ID
    NCT05835713
    Conditions
    Respiratory Disease; Tracheal Stenosis; Endobronchial Mass
    Interventions
    Remimazolam besylate; Propofol
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Withdrawn
    Start
    2023-04
    Completion
    2024-04
    Enrolment
    0

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionRespiratory Disease; Tracheal Stenosis; Endobronchial Mass
    InterventionRemimazolam besylate; Propofol
    PhaseNot applicable
    Registry statusWithdrawn

  • Effect of Rematazolam Besylate, Propofol, and Sevoflurane Perioperative Sedation on Incidence of Emergence Agitation and Hemodynamics in Patients Undergoing Laparoscopic Abdominal Surgery

    NCT05624424 · start 2022-11-15

    Registered record
    Registry ID
    NCT05624424
    Conditions
    Emergence Agitation; Remimazolam Besylate; Perioperative Sedation; Laparoscopic Abdominal Surgery; Anesthesia, General
    Interventions
    Rematazolam Besylate; Propofol; Sevoflurane; Sufentanil; Cisatracurium Besylate; Remifentanil
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Unknown
    Start
    2022-11-15
    Completion
    2023-10-31
    Enrolment
    1,317

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionEmergence Agitation; Remimazolam Besylate; Perioperative Sedation; Laparoscopic Abdominal Surgery +1 more
    InterventionRematazolam Besylate; Propofol; Sevoflurane; Sufentanil +2 more
    PhasePhase 4
    Registry statusUnknown

  • Remimazolam vs Propofol as an Induction Agent for Morbid Obesity Patients

    NCT05856617 · start 2022-10-25

    Registered record
    Registry ID
    NCT05856617
    Conditions
    Remimazolam; Desflurane; Morbid Obesity; Sleeve Gastrectomy; General Anesthesia
    Interventions
    Remimazolam besylate
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Unknown
    Start
    2022-10-25
    Completion
    2023-09-12
    Enrolment
    88

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionRemimazolam; Desflurane; Morbid Obesity; Sleeve Gastrectomy +1 more
    InterventionRemimazolam besylate
    PhasePhase 4
    Registry statusUnknown

  • Electroencephalographic Profiles During General Anesthesia: a Comparative Study of Remimazolam and Propofol

    NCT05533567 · start 2022-10-01

    Registered record
    Registry ID
    NCT05533567
    Conditions
    General Anesthesia; Electroencephalography; Laparoscopic Cholecystectomy; Remimazolam; Propofol
    Interventions
    Remimazolam; Propofol
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Unknown
    Start
    2022-10-01
    Completion
    2023-01-31
    Enrolment
    12

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionGeneral Anesthesia; Electroencephalography; Laparoscopic Cholecystectomy; Remimazolam +1 more
    InterventionRemimazolam; Propofol
    PhaseNot applicable
    Registry statusUnknown

  • Differential Effects of Remimazolam and Propofol on Dynamic Cerebral Autoregulation During General Anesthesia

    NCT05533580 · start 2022-10-01

    Registered record
    Registry ID
    NCT05533580
    Conditions
    General Anesthesia; Laparoscopic Cholecystectomy; Remimazolam; Propofol; Dynamic Cerebral Autoregulation
    Interventions
    Remimazolam; Propofol
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Unknown
    Start
    2022-10-01
    Completion
    2023-01-31
    Enrolment
    50

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionGeneral Anesthesia; Laparoscopic Cholecystectomy; Remimazolam; Propofol +1 more
    InterventionRemimazolam; Propofol
    PhaseNot applicable
    Registry statusUnknown

  • Efficacy and Safety of Remimazolam Besylate Versus Propofol for Sedation in Critically Ill Patients With Deep Sedation

    NCT05539521 · start 2022-09-05

    Registered record
    Registry ID
    NCT05539521
    Conditions
    Critically Ill; Deep Sedation
    Interventions
    Remimazolam Besylate; Propofol
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Unknown
    Start
    2022-09-05
    Completion
    2023-03
    Enrolment
    60

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCritically Ill; Deep Sedation
    InterventionRemimazolam Besylate; Propofol
    PhasePhase 2
    Registry statusUnknown

  • Esketamine Induction Intubation in ICU Patients.

    NCT05464979 · start 2022-08-27

    Registered record
    Registry ID
    NCT05464979
    Conditions
    Critically Ill Patients
    Interventions
    Esketamine Hydrochloride 28 Mg in 0.2 mL NASAL SOLUTION [Spravato]; midazolam, fentanyl
    Study type
    INTERVENTIONAL
    Phase
    Early phase 1
    Registry status
    Completed
    Start
    2022-08-27
    Completion
    2023-06-28
    Enrolment
    80

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCritically Ill Patients
    InterventionEsketamine Hydrochloride 28 Mg in 0.2 mL NASAL SOLUTION [Spravato]; midazolam, fentanyl
    PhaseEarly phase 1
    Registry statusCompleted

  • Effect of Remimazolam vs Sevoflurane Anesthesia on Incidence of Emergence Agitation and Complications in Children Undergoing Ophthalmic Surgery

    NCT05527314 · start 2022-08-23

    Registered record
    Registry ID
    NCT05527314
    Conditions
    Emergence Agitation; Remimazolam; Sevoflurane; Pediatric Ophthalmic Surgery; Anesthesia, General
    Interventions
    Remimazolam; Sevoflurane; Fentanyl; Cisatracurium Besylate; Remifentanil
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2022-08-23
    Completion
    2023-02-07
    Enrolment
    110

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionEmergence Agitation; Remimazolam; Sevoflurane; Pediatric Ophthalmic Surgery +1 more
    InterventionRemimazolam; Sevoflurane; Fentanyl; Cisatracurium Besylate +1 more
    PhaseNot applicable
    Registry statusCompleted

  • Comparison of Remimazolam With Flumazenil vs. Propofol During RFCA for Atrial Fibrillation

    NCT05397886 · start 2022-08-02

    Registered record
    Registry ID
    NCT05397886
    Conditions
    Recovery
    Interventions
    Remimazolam Besylate; Flumazenil; Propofol
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2022-08-02
    Completion
    2023-04-25
    Enrolment
    54

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionRecovery
    InterventionRemimazolam Besylate; Flumazenil; Propofol
    PhaseNot applicable
    Registry statusCompleted

  • Comparison of Recovery From General Anesthesia in Remimazolam With Flumazenil vs. Propofol

    NCT05435911 · start 2022-08-02

    Registered record
    Registry ID
    NCT05435911
    Conditions
    Recovery
    Interventions
    REMIMAZOLAM BESYLATE 2.5 Mg in 1 mL INTRAVENOUS INJECTION, POWDER, LYOPHILIZED, for SOLUTION [BYFAVO]; Flumazenil; Propofol
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2022-08-02
    Completion
    2022-12-21
    Enrolment
    66

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionRecovery
    InterventionREMIMAZOLAM BESYLATE 2.5 Mg in 1 mL INTRAVENOUS INJECTION, POWDER, LYOPHILIZED, for SOLUTION [BYFAVO]; Flumazenil; Propofol
    PhaseNot applicable
    Registry statusCompleted

  • Remimazolam vs Desflurane for General Anesthesia for Ablation of Arrhythmia

    NCT05486377 · start 2022-08-02

    Registered record
    Registry ID
    NCT05486377
    Conditions
    Remimazolam; Desflurane; Cryoablation; Arrhythmia; General Anesthesia
    Interventions
    Remimazolam besylate
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2022-08-02
    Completion
    2023-05-19
    Enrolment
    96

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionRemimazolam; Desflurane; Cryoablation; Arrhythmia +1 more
    InterventionRemimazolam besylate
    PhasePhase 4
    Registry statusCompleted

  • Effect of Remimazolam on Motor Evoked Potential

    NCT05453955 · start 2022-08-01

    Registered record
    Registry ID
    NCT05453955
    Conditions
    Spine Disease
    Interventions
    Propofol; Remimazolam Besylate
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2022-08-01
    Completion
    2023-02-07
    Enrolment
    20

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSpine Disease
    InterventionPropofol; Remimazolam Besylate
    PhaseNot applicable
    Registry statusCompleted

  • Effect of Remimazolam and Propofol on Hemodynamic Stability During Anesthesia Induction in OPCAB Patients

    NCT05423951 · start 2022-07-26

    Registered record
    Registry ID
    NCT05423951
    Conditions
    Hemodynamic Instability
    Interventions
    REMIMAZOLAM BESYLATE 2.5 Mg in 1 mL INTRAVENOUS INJECTION, POWDER, LYOPHILIZED, for SOLUTION [BYFAVO]; Propofol; Rocuronium; Sufentanil
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2022-07-26
    Completion
    2023-11-08
    Enrolment
    106

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHemodynamic Instability
    InterventionREMIMAZOLAM BESYLATE 2.5 Mg in 1 mL INTRAVENOUS INJECTION, POWDER, LYOPHILIZED, for SOLUTION [BYFAVO]; Propofol; Rocuronium; Sufentanil
    PhaseNot applicable
    Registry statusCompleted